{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:49:57Z","timestamp":1782208197622,"version":"3.54.5"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"St James's Hospital Foundation","award":["2657"],"award-info":[{"award-number":["2657"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04961-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:15:04Z","timestamp":1782195304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An analysis of succinate dehydrogenase B in pleural mesothelioma"],"prefix":"10.1007","volume":"17","author":[{"given":"Cormac J.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Rassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Rintoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"4961_CR1","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260\u201371.","journal-title":"Br J Ind Med"},{"issue":"5","key":"4961_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr., Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin"},{"key":"4961_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101872","volume":"40","author":"C Ledda","year":"2024","unstructured":"Ledda C, Loreto C, Lombardo C, Cardile V, Rapisarda V. Mesothelin methylation, soluble mesothelin related protein levels and inflammation profiling in workers chronically exposed to naturally occurring asbestos fibers. Transl Oncol. 2024;40:101872. https:\/\/doi.org\/10.1016\/j.tranon.2023.101872.","journal-title":"Transl Oncol"},{"issue":"10","key":"4961_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/blt.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716\u201324. https:\/\/doi.org\/10.2471\/blt.11.086678.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"4961_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1539\/joh.16-2002-ST","volume":"58","author":"C Ramazzini","year":"2016","unstructured":"Ramazzini C. The global health dimensions of asbestos and asbestos-related diseases. J Occup Health. 2016;58(2):220\u20133.","journal-title":"J Occup Health"},{"issue":"6","key":"4961_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","volume":"18","author":"J Huang","year":"2023","unstructured":"Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792\u2013802.","journal-title":"J Thorac Oncol"},{"key":"4961_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102900","volume":"98","author":"S Luan","year":"2025","unstructured":"Luan S, Wang Y. Global trends, future projections, and epidemiological associations of mesothelioma: a comprehensive analysis from 1980 to 2050. Cancer Epidemiol. 2025;98:102900. https:\/\/doi.org\/10.1016\/j.canep.2025.102900.","journal-title":"Cancer Epidemiol"},{"key":"4961_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108534","volume":"203","author":"W Jin","year":"2025","unstructured":"Jin W, Ding Z, Zhang M, Shen L, Wang H, Huang J, et al. The global burden of mesothelioma and its association with asbestos bans, 1990\u20132021: a population-based study. Lung Cancer. 2025;203:108534. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108534.","journal-title":"Lung Cancer"},{"issue":"6","key":"4961_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jtho.2023.03.013","volume":"18","author":"M Carbone","year":"2023","unstructured":"Carbone M, Yang H, Pass HI, Taioli E. Did the ban on asbestos reduce the incidence of mesothelioma? J Thorac Oncol. 2023;18(6):694\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2023.03.013.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4961_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","volume":"22","author":"J Stevenson","year":"2024","unstructured":"Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, et al. NCCN Guidelines\u00ae Insights: Mesothelioma: Pleural, Version 1.2024. J Natl Compr Canc Netw. 2024;22(2):72\u201381. https:\/\/doi.org\/10.6004\/jnccn.2024.0014.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"4961_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/op-25-00035","volume":"21","author":"HL Kindler","year":"2025","unstructured":"Kindler HL, Dagogo-Jack I, de Perrot M, Drazer MW, Ismaila N, Hassan R. Treatment of pleural mesothelioma: ASCO guideline clinical insights. JCO Oncol Pract. 2025;Op2500035. https:\/\/doi.org\/10.1200\/op-25-00035.","journal-title":"JCO Oncol Pract"},{"key":"4961_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116662","volume":"175","author":"B Nuvoli","year":"2024","unstructured":"Nuvoli B, Sacconi A, Bottillo G, Sciarra F, Libener R, Maconi A, et al. DHEA-S, androstenedione, 17-\u03b2-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: a preliminary investigation. Biomed Pharmacother. 2024;175:116662. https:\/\/doi.org\/10.1016\/j.biopha.2024.116662.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"4961_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/coc.0000000000000745","volume":"43","author":"N Alpert","year":"2020","unstructured":"Alpert N, van Gerwen M, Flores R, Taioli E. Gender differences in outcomes of patients with mesothelioma. Am J Clin Oncol. 2020;43(11):792\u20137. https:\/\/doi.org\/10.1097\/coc.0000000000000745.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"4961_CR14","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0007","volume":"3","author":"G Pinton","year":"2017","unstructured":"Pinton G, Moro L. Expression and therapeutic significance of estrogen receptor \u03b2 in malignant pleural mesothelioma. Future Sci OA. 2017;3(2):Fso175. https:\/\/doi.org\/10.4155\/fsoa-2017-0007.","journal-title":"Future Sci OA"},{"issue":"4","key":"4961_CR15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.21037\/jtd.2019.03.38","volume":"11","author":"JR Rodr\u00edguez-Cid","year":"2019","unstructured":"Rodr\u00edguez-Cid JR, Garc\u00eda-Acevedo O, Benjamin-Contreras J, Bonilla-Molina D, Flores-Mari\u00f1elarena RR, Mart\u00ednez-Barrera L, et al. Expression of estrogen receptor beta (ER\u03b2) and its prognostic value in pleural mesothelioma. J Thorac Dis. 2019;11(4):1456\u201364. https:\/\/doi.org\/10.21037\/jtd.2019.03.38.","journal-title":"J Thorac Dis"},{"issue":"11","key":"4961_CR16","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.Can-08-4523","volume":"69","author":"G Pinton","year":"2009","unstructured":"Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69(11):4598\u2013604. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4523.","journal-title":"Cancer Res"},{"key":"4961_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae070.368","author":"M Helali","year":"2024","unstructured":"Helali M, Abdelmotal A, Gobran NS, El Ghazaly H, Mahdy ME, Karim KA. Overexpression of estrogen receptor beta and its prognostic significance among malignant pleural mesothelioma patients. QJM: An International Journal of Medicine. 2024. https:\/\/doi.org\/10.1093\/qjmed\/hcae070.368.","journal-title":"QJM: An International Journal of Medicine"},{"issue":"30","key":"4961_CR18","doi-asserted-by":"publisher","first-page":"47116","DOI":"10.18632\/oncotarget.9964","volume":"7","author":"B Nuvoli","year":"2016","unstructured":"Nuvoli B, Sacconi A, Cortese G, Germoni S, Murer B, Galati R. Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models. Oncotarget. 2016;7(30):47116\u201326. https:\/\/doi.org\/10.18632\/oncotarget.9964.","journal-title":"Oncotarget"},{"issue":"11","key":"4961_CR19","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.21873\/anticanres.11177","volume":"36","author":"CJ Jennings","year":"2016","unstructured":"Jennings CJ, Zainal N, Dahlan IM, Kay EW, Harvey BJ, Thomas W. Tamoxifen suppresses the growth of malignant pleural mesothelioma cells. Anticancer Res. 2016;36(11):5905\u201313. https:\/\/doi.org\/10.21873\/anticanres.11177.","journal-title":"Anticancer Res"},{"key":"4961_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.32","volume":"2","author":"AG Manente","year":"2013","unstructured":"Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, et al. <article-title update=\"added\">Estrogen receptor \u03b2 activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis. 2013;2:e72. https:\/\/doi.org\/10.1038\/oncsis.2013.32.","journal-title":"Oncogenesis"},{"issue":"5","key":"4961_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.bbabio.2012.11.005","volume":"1827","author":"AS Hoekstra","year":"2013","unstructured":"Hoekstra AS, Bayley JP. The role of complex II in disease. Biochim Biophys Acta. 2013;1827(5):543\u201351. https:\/\/doi.org\/10.1016\/j.bbabio.2012.11.005.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4961_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-025-10023-9","volume":"41","author":"X Liu","year":"2025","unstructured":"Liu X, Deng M, Luo X, Li T, Ge Y, Li J, et al. Integrated machine learning survival framework develops a prognostic model based on macrophage-related genes and programmed cell death signatures in a multi-sample Kidney renal clear cell carcinoma. Cell Biol Toxicol. 2025;41(1):93. https:\/\/doi.org\/10.1007\/s10565-025-10023-9.","journal-title":"Cell Biol Toxicol"},{"key":"4961_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13048-014-0115-1","volume":"7","author":"L Chen","year":"2014","unstructured":"Chen L, Liu T, Zhang S, Zhou J, Wang Y, Di W. Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1\u03b1 pathway in human ovarian cancer in vitro. J Ovarian Res. 2014;7:115. https:\/\/doi.org\/10.1186\/s13048-014-0115-1.","journal-title":"J Ovarian Res"},{"issue":"1","key":"4961_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21361-6","volume":"8","author":"PL Tseng","year":"2018","unstructured":"Tseng PL, Wu WH, Hu TH, Chen CW, Cheng HC, Li CF, et al. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci Rep. 2018;8(1):3081. https:\/\/doi.org\/10.1038\/s41598-018-21361-6.","journal-title":"Sci Rep"},{"issue":"7","key":"4961_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.70066","volume":"240","author":"A Chatoff","year":"2025","unstructured":"Chatoff A, Kantner DS, Snyder NW, Rink L. Metabolic effects of succinate dehydrogenase loss in cancer. J Cell Physiol. 2025;240(7):e70066. https:\/\/doi.org\/10.1002\/jcp.70066.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4961_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00878-z","volume":"29","author":"CC Kuo","year":"2022","unstructured":"Kuo CC, Wu JY, Wu KK. Cancer-derived extracellular succinate: a driver of cancer metastasis. J Biomed Sci. 2022;29(1):93. https:\/\/doi.org\/10.1186\/s12929-022-00878-z.","journal-title":"J Biomed Sci"},{"issue":"4","key":"4961_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1210\/endrev\/bnae005","volume":"45","author":"O Uher","year":"2024","unstructured":"Uher O, Hadrava Vanova K, Ta\u00efeb D, Calsina B, Robledo M, Clifton-Bligh R, et al. The immune landscape of Pheochromocytoma and Paraganglioma: current advances and perspectives. Endocr Rev. 2024;45(4):521\u201352. https:\/\/doi.org\/10.1210\/endrev\/bnae005.","journal-title":"Endocr Rev"},{"key":"4961_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.mito.2014.06.001","volume":"19","author":"MS Hwang","year":"2014","unstructured":"Hwang MS, Rohlena J, Dong LF, Neuzil J, Grimm S. Powerhouse down: complex II dissociation in the respiratory chain. Mitochondrion. 2014;19:20\u20138. https:\/\/doi.org\/10.1016\/j.mito.2014.06.001.","journal-title":"Mitochondrion"},{"key":"4961_CR29","first-page":"110","volume":"43","author":"IO Farah","year":"2007","unstructured":"Farah IO. Differential modulation of intracellular energetics in A549 and MRC-5 cells. Biomed Sci Instrum. 2007;43:110\u20135.","journal-title":"Biomed Sci Instrum"},{"issue":"2","key":"4961_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/bj20071162","volume":"409","author":"FL Muller","year":"2008","unstructured":"Muller FL, Liu Y, Abdul-Ghani MA, Lustgarten MS, Bhattacharya A, Jang YC, et al. High rates of superoxide production in skeletal-muscle mitochondria respiring on both complex I- and complex II-linked substrates. Biochem J. 2008;409(2):491\u20139. https:\/\/doi.org\/10.1042\/bj20071162.","journal-title":"Biochem J"},{"issue":"1","key":"4961_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/PAI.0b013e31828bfdd3","volume":"22","author":"M Miettinen","year":"2014","unstructured":"Miettinen M, Sarlomo-Rikala M, McCue P, Czapiewski P, Langfort R, Waloszczyk P, et al. Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2014;22(1):31\u20136. https:\/\/doi.org\/10.1097\/PAI.0b013e31828bfdd3.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"4961_CR32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/bjc.2013.66","volume":"108","author":"LE Dalton","year":"2013","unstructured":"Dalton LE, Clarke HJ, Knight J, Lawson MH, Wason J, Lomas DA, et al. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer. 2013;108(6):1340\u20137. https:\/\/doi.org\/10.1038\/bjc.2013.66.","journal-title":"Br J Cancer"},{"issue":"4","key":"4961_CR33","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1128\/mcb.20.4.1436-1447.2000","volume":"20","author":"MA Dickson","year":"2000","unstructured":"Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000;20(4):1436\u201347. https:\/\/doi.org\/10.1128\/mcb.20.4.1436-1447.2000.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"4961_CR34","first-page":"979","volume":"134","author":"Y Ke","year":"1989","unstructured":"Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol. 1989;134(5):979\u201391.","journal-title":"Am J Pathol"},{"issue":"4","key":"4961_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-m","volume":"59","author":"HI Pass","year":"1995","unstructured":"Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995;59(4):835\u201344. https:\/\/doi.org\/10.1016\/0003-4975(95)00045-m.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"4961_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1165\/ajrcmb.26.2.4673","volume":"26","author":"P Cacciotti","year":"2002","unstructured":"Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol. 2002;26(2):189\u201393. https:\/\/doi.org\/10.1165\/ajrcmb.26.2.4673.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4961_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcb.240630505","volume":"24","author":"RM Phelps","year":"1996","unstructured":"Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, et al. NCI-Navy medical oncology branch cell line data base. J Cell Biochem Suppl. 1996;24:32\u201391. https:\/\/doi.org\/10.1002\/jcb.240630505.","journal-title":"J Cell Biochem Suppl"},{"issue":"9","key":"4961_CR38","first-page":"2610","volume":"52","author":"RA Metcalf","year":"1992","unstructured":"Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992;52(9):2610\u20135.","journal-title":"Cancer Res"},{"issue":"2","key":"4961_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ijc.2910470219","volume":"47","author":"LS Manning","year":"1991","unstructured":"Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 1991;47(2):285\u201390. https:\/\/doi.org\/10.1002\/ijc.2910470219.","journal-title":"Int J Cancer"},{"issue":"3","key":"4961_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00418-004-0701-1.","volume":"122","author":"MM Philippeaux","year":"2004","unstructured":"Philippeaux MM, Pache JC, Dahoun S, Barnet M, Robert JH, Mau\u00ebl J, et al. Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis. Histochem Cell Biol. 2004;122(3):249\u201360. https:\/\/doi.org\/10.1007\/s00418-004-0701-1.","journal-title":"Histochem Cell Biol"},{"issue":"5","key":"4961_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x.","volume":"97","author":"N Usami","year":"2006","unstructured":"Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97(5):387\u201394. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00184.x.","journal-title":"Cancer Sci"},{"issue":"3","key":"4961_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x.","volume":"98","author":"T Taniguchi","year":"2007","unstructured":"Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007;98(3):438\u201346. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00386.x.","journal-title":"Cancer Sci"},{"issue":"7","key":"4961_CR43","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","volume":"30","author":"K Kawaguchi","year":"2009","unstructured":"Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30(7):1097\u2013105. https:\/\/doi.org\/10.1093\/carcin\/bgp097.","journal-title":"Carcinogenesis"},{"issue":"6","key":"4961_CR44","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/0003-4975(94)90090-6","volume":"57","author":"WR Smythe","year":"1994","unstructured":"Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994;57(6):1395\u2013401. https:\/\/doi.org\/10.1016\/0003-4975(94)90090-6.","journal-title":"Ann Thorac Surg"},{"key":"4961_CR45","unstructured":"Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L et al. Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, editors. Assay guidance manual. Bethesda MD2004."},{"issue":"3","key":"4961_CR46","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8(3):138\u201340.","journal-title":"Pathologe"},{"key":"4961_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-014-0221-9","volume":"9","author":"N Fedchenko","year":"2014","unstructured":"Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221. https:\/\/doi.org\/10.1186\/s13000-014-0221-9.","journal-title":"Diagn Pathol"},{"issue":"2","key":"4961_CR48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304.e6. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022.","journal-title":"Cell"},{"issue":"6","key":"4961_CR49","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/s0002-9440(10)62492-3","volume":"166","author":"GJ Gordon","year":"2005","unstructured":"Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166(6):1827\u201340. https:\/\/doi.org\/10.1016\/s0002-9440(10)62492-3.","journal-title":"Am J Pathol"},{"issue":"6","key":"4961_CR50","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.can-05-3907","volume":"66","author":"F Lopez-Rios","year":"2006","unstructured":"Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66(6):2970\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-05-3907.","journal-title":"Cancer Res"},{"key":"4961_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18\u201327. https:\/\/doi.org\/10.1016\/j.neo.2022.01.001.","journal-title":"Neoplasia"},{"issue":"4","key":"4961_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316. https:\/\/doi.org\/10.1038\/ng.3520.","journal-title":"Nat Genet"},{"issue":"1","key":"4961_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101938","volume":"39","author":"C Lussey-Lepoutre","year":"2025","unstructured":"Lussey-Lepoutre C, Pacak K, Grossman A, Taieb D, Amar L. Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients. Best Pract Res Clin Endocrinol Metab. 2025;39(1):101938. https:\/\/doi.org\/10.1016\/j.beem.2024.101938.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"4961_CR54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372. https:\/\/doi.org\/10.1038\/ng.855.","journal-title":"Nat Genet"},{"issue":"1","key":"4961_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41379-021-00920-9","volume":"35","author":"JR Naso","year":"2022","unstructured":"Naso JR, Tessier-Cloutier B, Senz J, Huntsman DG, Churg A. Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. Mod Pathol. 2022;35(1):77\u201381. https:\/\/doi.org\/10.1038\/s41379-021-00920-9.","journal-title":"Mod Pathol"},{"issue":"11","key":"4961_CR56","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","volume":"20","author":"M Carbone","year":"2025","unstructured":"Carbone M, Minaai M, Kittaneh M, Krausz T, Miettinen MM, Pan Hammarstr\u00f6m Q, et al. Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations. J Thorac Oncol. 2025;20(11):1683\u201398. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.020.","journal-title":"J Thorac Oncol"},{"key":"4961_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1161995","volume":"5","author":"Y Sekido","year":"2023","unstructured":"Sekido Y, Sato T. NF2 alteration in mesothelioma. Front Toxicol. 2023;5:1161995. https:\/\/doi.org\/10.3389\/ftox.2023.1161995.","journal-title":"Front Toxicol"},{"issue":"W1","key":"4961_CR58","doi-asserted-by":"publisher","first-page":"W534","DOI":"10.1093\/nar\/gkaf388","volume":"53","author":"H Cui","year":"2025","unstructured":"Cui H, Zhao G, Lu Y, Zuo S, Duan D, Luo X, et al. TIMER3: an enhanced resource for tumor immune analysis. Nucleic Acids Res. 2025;53(W1):W534-w41. https:\/\/doi.org\/10.1093\/nar\/gkaf388.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"4961_CR59","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"4961_CR60","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3892\/ijmm.2012.1138","volume":"30","author":"SG Gray","year":"2012","unstructured":"Gray SG, Baird AM, O\u2019Kelly F, Nikolaidis G, Almgren M, Meunier A, et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int J Mol Med. 2012;30(6):1505\u201311. https:\/\/doi.org\/10.3892\/ijmm.2012.1138.","journal-title":"Int J Mol Med"},{"issue":"269","key":"4961_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"4961_CR62","doi-asserted-by":"publisher","unstructured":"Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277\u201388. https:\/\/doi.org\/10.2217\/epi-2017-0118.","DOI":"10.2217\/epi-2017-0118"},{"key":"4961_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-015-0014-8","volume":"8","author":"A D\u00edez-Villanueva","year":"2015","unstructured":"D\u00edez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin. 2015;8:22. https:\/\/doi.org\/10.1186\/s13072-015-0014-8.","journal-title":"Epigenetics Chromatin"},{"key":"4961_CR64","doi-asserted-by":"publisher","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0307.","DOI":"10.1158\/0008-5472.Can-17-0307"},{"issue":"1","key":"4961_CR65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(1):509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4961_CR66","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.Mct-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0386.","journal-title":"Mol Cancer Ther"},{"key":"4961_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003032","author":"J Harber","year":"2021","unstructured":"Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003032.","journal-title":"J Immunother Cancer"},{"key":"4961_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113457","volume":"196","author":"D de Miguel-Perez","year":"2024","unstructured":"de Miguel-Perez D, Pickering EM, Malapelle U, Grier W, Pepe F, Pisapia P, et al. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma. Eur J Cancer. 2024;196:113457. https:\/\/doi.org\/10.1016\/j.ejca.2023.113457.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4961_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06193-z","volume":"23","author":"F Torricelli","year":"2025","unstructured":"Torricelli F, Spada F, Bishop C, Todd K, Nonaka D, Petrov N, et al. The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes. J Transl Med. 2025;23(1):208. https:\/\/doi.org\/10.1186\/s12967-025-06193-z.","journal-title":"J Transl Med"},{"key":"4961_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.564796","volume":"10","author":"H Feng","year":"2020","unstructured":"Feng H, Shen W. ACAA1 is a predictive factor of survival and is correlated with T cell infiltration in non-small cell lung cancer. Front Oncol. 2020;10:564796. https:\/\/doi.org\/10.3389\/fonc.2020.564796.","journal-title":"Front Oncol"},{"issue":"1","key":"4961_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06891-2","volume":"7","author":"S Li","year":"2024","unstructured":"Li S, Peng Y, Chen M, Zhao Y, Xiong Y, Li J, et al. Facilitating integrative and personalized oncology omics analysis with UCSCXenaShiny. Commun Biol. 2024;7(1):1200. https:\/\/doi.org\/10.1038\/s42003-024-06891-2.","journal-title":"Commun Biol"},{"key":"4961_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17244020","author":"M Delsignore","year":"2025","unstructured":"Delsignore M, Cassinari G, Revello S, Cerbone L, Grosso F, Arsura M, et al. Determinants of response to immune checkpoint blockade in pleural mesothelioma: molecular, immunological, and clinical perspectives. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17244020.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4961_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167361","volume":"434","author":"M Ziemann","year":"2022","unstructured":"Ziemann M, Lim SC, Kang Y, Samuel S, Sanchez IL, Gantier M, et al. MicroRNA-101-3p modulates mitochondrial metabolism via the regulation of complex II assembly. J Mol Biol. 2022;434(2):167361. https:\/\/doi.org\/10.1016\/j.jmb.2021.167361.","journal-title":"J Mol Biol"},{"key":"4961_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1003-y","volume":"19","author":"X Zhao","year":"2019","unstructured":"Zhao X, Li Y, Zhou Y. MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB. Cancer Cell Int. 2019;19:287. https:\/\/doi.org\/10.1186\/s12935-019-1003-y.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4961_CR75","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1530\/erc-12-0183","volume":"20","author":"AA de Cubas","year":"2013","unstructured":"de Cubas AA, Leandro-Garc\u00eda LJ, Schiavi F, Mancikova V, Comino-M\u00e9ndez I, Inglada-P\u00e9rez L, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer. 2013;20(4):477\u201393. https:\/\/doi.org\/10.1530\/erc-12-0183.","journal-title":"Endocr Relat Cancer"},{"key":"4961_CR76","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.biopha.2017.05.134","volume":"92","author":"S Liu","year":"2017","unstructured":"Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K, et al. MiR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis. Biomed Pharmacother. 2017;92:1119\u201327. https:\/\/doi.org\/10.1016\/j.biopha.2017.05.134.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4961_CR77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/erc-11-0308","volume":"19","author":"E Patterson","year":"2012","unstructured":"Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, et al. The microrna expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer. 2012;19(2):157\u201366. https:\/\/doi.org\/10.1530\/erc-11-0308.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4961_CR78","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/erc-13-0519","volume":"21","author":"VH Tsang","year":"2014","unstructured":"Tsang VH, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014;21(3):415\u201326. https:\/\/doi.org\/10.1530\/erc-13-0519.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4961_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07830-7","volume":"16","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Wu Y, Li C, Huang Z, Peng D, Wu Z, et al. Circ0515 reprogramming mitochondrial succinate metabolism and promotes lung adenocarcinoma progression through regulating SDHB. Cell Death Dis. 2025;16(1):497. https:\/\/doi.org\/10.1038\/s41419-025-07830-7.","journal-title":"Cell Death Dis"},{"issue":"28","key":"4961_CR80","doi-asserted-by":"publisher","first-page":"25121","DOI":"10.18632\/oncotarget.4486","volume":"6","author":"AG Manente","year":"2015","unstructured":"Manente AG, Pinton G, Zonca S, Cilli M, Rinaldi M, Daga A, et al. Intracellular lactate-mediated induction of estrogen receptor beta (ER\u03b2) in biphasic malignant pleural mesothelioma cells. Oncotarget. 2015;6(28):25121\u201334. https:\/\/doi.org\/10.18632\/oncotarget.4486.","journal-title":"Oncotarget"},{"key":"4961_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-227","volume":"13","author":"G Pinton","year":"2014","unstructured":"Pinton G, Manente AG, Daga A, Cilli M, Rinaldi M, Nilsson S, et al. Agonist activation of estrogen receptor beta (ER\u03b2) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. Mol Cancer. 2014;13:227. https:\/\/doi.org\/10.1186\/1476-4598-13-227.","journal-title":"Mol Cancer"},{"issue":"12","key":"4961_CR82","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.18632\/oncotarget.7321","volume":"7","author":"G Pinton","year":"2016","unstructured":"Pinton G, Zonca S, Manente AG, Cavaletto M, Borroni E, Daga A, et al. SIRT1 at the crossroads of AKT1 and ER\u03b2 in malignant pleural mesothelioma cells. Oncotarget. 2016;7(12):14366\u201379. https:\/\/doi.org\/10.18632\/oncotarget.7321.","journal-title":"Oncotarget"},{"issue":"10431","key":"4961_CR83","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/s0140-6736(23)02554-0","volume":"403","author":"E Baudin","year":"2024","unstructured":"Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. 2024;403(10431):1061\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(23)02554-0.","journal-title":"Lancet"},{"issue":"11","key":"4961_CR84","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","volume":"6","author":"SA Laurie","year":"2011","unstructured":"Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC clinical trials group. J Thorac Oncol. 2011;6(11):1950\u20134. https:\/\/doi.org\/10.1097\/JTO.0b013e3182333df5.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4961_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-012-2008-6","volume":"71","author":"DR Camidge","year":"2013","unstructured":"Camidge DR, Blais N, Jonker DJ, Souli\u00e8res D, Doebele RC, Ruiz-Garcia A, et al. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol. 2013;71(2):307\u201319. https:\/\/doi.org\/10.1007\/s00280-012-2008-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"4961_CR86","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","volume":"7","author":"AK Nowak","year":"2012","unstructured":"Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1449\u201356. https:\/\/doi.org\/10.1097\/JTO.0b013e31825f22ee.","journal-title":"J Thorac Oncol"},{"key":"4961_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1026185","volume":"13","author":"E Stern","year":"2022","unstructured":"Stern E, Caruso S, Meiller C, Mishalian I, Hirsch TZ, Bayard Q, et al. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics. Front Immunol. 2022;13:1026185. https:\/\/doi.org\/10.3389\/fimmu.2022.1026185.","journal-title":"Front Immunol"},{"key":"4961_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.879278","volume":"10","author":"S Zhang","year":"2022","unstructured":"Zhang S, Li S, Wei Y, Xiong Y, Liu Q, Hu Z, et al. Identification of potential antigens for developing mRNA vaccine for immunologically cold mesothelioma. Front Cell Dev Biol. 2022;10:879278. https:\/\/doi.org\/10.3389\/fcell.2022.879278.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"4961_CR89","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10637-012-9799-5","volume":"30","author":"A Ruban","year":"2012","unstructured":"Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs. 2012;30(6):2226\u201335. https:\/\/doi.org\/10.1007\/s10637-012-9799-5.","journal-title":"Invest New Drugs"},{"key":"4961_CR90","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbacli.2016.03.005","volume":"5","author":"RH Swerdlow","year":"2016","unstructured":"Swerdlow RH, Bothwell R, Hutfles L, Burns JM, Reed GA. Tolerability and pharmacokinetics of oxaloacetate 100\u00a0mg capsules in Alzheimer\u2019s subjects. BBA Clin. 2016;5:120\u20133. https:\/\/doi.org\/10.1016\/j.bbacli.2016.03.005.","journal-title":"BBA Clin"},{"issue":"1","key":"4961_CR91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/alz.12156","volume":"17","author":"ED Vidoni","year":"2021","unstructured":"Vidoni ED, Choi IY, Lee P, Reed G, Zhang N, Pleen J, et al. Safety and target engagement profile of two oxaloacetate doses in Alzheimer\u2019s patients. Alzheimer\u2019s & Dementia. 2021;17(1):7\u201317. https:\/\/doi.org\/10.1002\/alz.12156.","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"4961_CR92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1179\/1351000213y.0000000064","volume":"19","author":"J Kovarova","year":"2014","unstructured":"Kovarova J, Bajzikova M, Vondrusova M, Stursa J, Goodwin J, Nguyen M, et al. Mitochondrial targeting of alpha-tocopheryl succinate enhances its anti-mesothelioma efficacy. Redox Rep. 2014;19(1):16\u201325. https:\/\/doi.org\/10.1179\/1351000213y.0000000064.","journal-title":"Redox Rep"},{"issue":"8","key":"4961_CR93","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.tiv.2011.05.023","volume":"25","author":"S Martinotti","year":"2011","unstructured":"Martinotti S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011;25(8):1568\u201374. https:\/\/doi.org\/10.1016\/j.tiv.2011.05.023.","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"4961_CR94","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.bbrc.2006.03.052","volume":"343","author":"J Neuzil","year":"2006","unstructured":"Neuzil J, Dong LF, Wang XF, Zingg JM. Tocopherol-associated protein-1 accelerates apoptosis induced by \u03b1-tocopheryl succinate in mesothelioma cells. Biochem Biophys Res Commun. 2006;343(4):1113\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2006.03.052.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"4961_CR95","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ijc.20062","volume":"109","author":"M Tomasetti","year":"2004","unstructured":"Tomasetti M, Gellert N, Procopio A, Neuzil J. A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int J Cancer. 2004;109(5):641\u20132. https:\/\/doi.org\/10.1002\/ijc.20062.","journal-title":"Int J Cancer"},{"issue":"8","key":"4961_CR96","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6601707","volume":"90","author":"M Tomasetti","year":"2004","unstructured":"Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J, et al. \u03b1-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer. 2004;90(8):1644\u201353. https:\/\/doi.org\/10.1038\/sj.bjc.6601707.","journal-title":"Br J Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04961-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04961-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04961-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:19:17Z","timestamp":1782206357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04961-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4961"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04961-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, in-line with national and international guidelines and approved by the authors\u2019 respective institutional board(s). The study was conducted in accordance with the Declaration of Helsinki, in-line with national and international guidelines and approved by the authors\u2019 institutional board Surgical specimens were obtained as discarded tumor samples from patients who had undergone extended pleuro-pneumonectomy at Glenfield Hospital, Leicester, UK. Benign specimens were acquired from patients never diagnosed with Me. Informed consent was obtained from each patient, and the study was conducted after formal approval from the relevant Hospital Ethics Committee (Leicestershire REC references 6742 and 6948). For FFPE, ethical approval for the use of samples and data collection was granted by the Royal Papworth Hospital Research Ethics Committee (REC reference 09\/H0311\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Non-financial interests: Steven Gray is an editorial board member of Discover Oncology.All other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"934"}}